‡a
Author's Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
‡a
Author's Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
‡a
Author's Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial
‡a
safetyandclinicalactivityofanewantipdl1antibodyasmonotherapyorcombinedwithtargetedtherapyinadvancedsolidtumorsthepactphaseiaibtrial
‡A
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial
‡9
1
‡a
phase1doseescalationstudyofscb01aamicrotubuleinhibitorwithvasculardisruptingactivityinpatientswithadvancedsolidtumors
‡A
Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors
‡9
1
‡a
phase1studyofcapmatinibinmetpositivesolidtumorpatientsdoseescalationandexpansionofselectedcohorts
‡A
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
‡9
1
‡a
outcomesinpatientswithnonsmallcelllungcancerandacquiredthr790metmutationtreatedwithosimertinibagenomicstudy
‡A
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
‡9
1
‡a
bestresponseaccordingtorecistduring1lineegfrtkitreatmentpredictssurvivalinegfrmutationpositivenonsmallcelllungcancerpatients
‡A
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
‡9
1
